Overview
Lifordi Immunotherapeutics, a clinical-stage biotech company developing antibody-drug conjugates for autoimmune disorders, secured $112 million in funding led by Sanofi Ventures, with participation from Arch Ventures, 5AM Ventures, and Atlas Venture. The investment supports a Phase 1 study of LFD-200, targeting rheumatoid arthritis while minimizing glucocorticoid toxicity.
Products
Loading...
Recent Deals
Investors: Sanofi Ventures, Arch Ventures, 5AM Ventures, Atlas Venture
Lifordi Immunotherapeutics, a clinical-stage biotech company developing antibody-drug conjugates for autoimmune disorders, secured $112 million in funding led by Sanofi Ventures, with participation from Arch Ventures, 5AM Ventures, and Atlas Venture. The investment supports a Phase 1 study of LFD-200, targeting rheumatoid arthritis while minimizing glucocorticoid toxicity.